Analysis of Interferon-Gamma Release Assay Results for Latent Tuberculosis Infection Diagnosis at a Referral Clinical Laboratory in South Korea

Tae Soung Kim, Ga Yeon Kim, Young Ki Lee and Jae Kyung Kim

1Department of Clinical Pathology, Graduate School of Dankook University, Cheonan, Republic of Korea
2Department of Public Health, Graduate School of Dankook University, Cheonan, Republic of Korea
3Department of Biomedical Laboratory Science, College of Health and Welfare, Dankook University, Cheonan, Republic of Korea

Abstract: The world health organization states that individuals with Latent Tuberculosis Infection (LTBI) are infected with Tuberculosis (TB) bacteria but do not show symptoms of active disease. However, they are at possibility of developing vigorous TB and potentially transmitting the illness to others. In 2018, South Korea reported a 14.8% positivity rate in LTBI screening, with higher rates observed among older individuals, those with lower incomes and women. Furthermore, approximately one in four people worldwide has LTBI. LTBI within certain groups is often the result of prolonged, cumulative and close contact with infected individuals. In this study, we aimed to analyze the current scenario regarding LTBI in South Korea, where large groups are being tested utilizing the Interferon-Gamma Release Assay (IGRA). From 2019-2022, 219,459 cases with IGRA results obtained from a referral clinical laboratory in Yongin city were investigated. This research was accepted by the Institutional Review Board (IRB) of Dankook university. The specimens were collected in QuantiFERON® gold plus Tubes (TB) (Qiagen GmbH, Hilden, Germany) and interferon-gamma activity was measured using an enzyme-linked immunosorbent assay (Dynex technologies, Inc., Chantilly, Virginia, USA). multinomial logistic regression analysis was performed to study the association among age, sex and LTBI confirmed by IGRAs. The p-value for sex was less than 0.001, indicating a significantly higher positivity rate in women than in men. Additionally, the positivity rate decreased in both sexes from 2019-2022. Notably, the highest positivity rates were observed in 50-59-year age set, with men at 1.32% and women at 2.33%. As testing frequency increased, the probability of detecting positive results also increased. Continuous IGRA testing is recommended for individuals in the 50-59-year age group. Regular and extensive testing is recommended for healthcare workers, military personnel, prisoners and students. Therefore, the pros and cons of IGRA can be analyzed and it is believed that it can be helpful for public health.

Keywords: Interferon-Gamma, Interferon-Gamma Releasing Assay, Latent Tuberculosis Infection, Mycobacterium Tuberculosis, Quantiferon Tb Gold Plus

Introduction

According to the world health organization, individuals with Latent Tuberculosis Infection (LTBI) are infected with Tuberculosis (TB) bacteria but do not show symptoms of active TB. However, individuals with LTBI are at a possibility of having a vigorous TB and can potentially infect others (WHO, 2019). According to global estimates, one in four individuals has LTBI; therefore, expanding effective LTBI treatment is necessary to reduce the global incidence of TB, as outlined in the “end TB strategy,” along with the rapid expansion of TB-preventive treatment in high-risk populations (WHO, 2019). In South Korea, the rate of
positive results for LTBI screening was 14.8% (12,660 of 857,765 individuals tested) in 2018, with higher positivity rates observed among older individuals, those with lower income and women. The treatment initiation rate in positive cases, which represents the proportion of individuals who begin treatment upon receiving a positive result, stands at only 31.7% (MHW, 2019). Although TB is preventable, action toward LTBI is underutilized. To achieve the goal of TB elimination, it is crucial to prioritize screening of high-risk groups, especially individuals from countries with high TB incidence rates and provide patient-centered support (Bruxvoort et al., 2023). The prevalence of LTBI is significantly increased (or higher) among contacts within households where pulmonary TB is present (Sangma et al., 2023). Furthermore, workplace-associated LTBI may result from work-related interactions and continued, accumulative and near interaction with sick colleagues (Ruamtham et al., 2023). Additionally, it is particularly important to detect LTBI in high-risk populations, including those in crowded settings such as correctional facilities and Healthcare Workers (HCWs).

Patients with LTBI are asymptomatic and non-infectious; however, they are at a possibility of having vigorous TB (Pagaduan and Altawallbeh, 2023). Therefore, it is important to prevent the incidence and transmission of TB. Additionally, treatment of LTBI has been exposed to lessen the possibility of progression to active TB (Jonas et al., 2023; Saint-Pierre et al., 2023).

The Interferon-Gamma Release Assay (IGRA) has shown moderate compassion and high specificity in detecting LTBI. A use of QuantiFERON® TB Gold Plus (QFT-Plus) is appropriate for LTBI discovery in countries burdened with TB (Matucci et al., 2023; Rudeeaneksin et al., 2023). The global estimate is that one in four individuals have LTBI. An analysis of the current scenario of LTBI in South Korea, which screens numerous groups through IGRA’s using the QFT-Plus tube kit to achieve the goal of TB eradication, was deemed necessary and was performed.

Materials and Methods

Samples for testing originating from hospitals across the country (including primary hospitals with 30 beds or fewer, secondary hospitals with 30-300 beds and tertiary hospitals with more than 300 beds) were sent to a referral clinical laboratory in Yongin city equipped for LTBI testing. We analyzed trends in sex-specific positivity rates based on age using IGRA results recorded from January 01, 2019, -December 31, 2022. Overall, 219,459 patients are involved: 193,866 tested negative, 22,662 tested positive and 2,931 showed indeterminate results (QuantiFERON®-TB Gold Plus, 2023). Samples were collected using QFT-Plus tubes (Qiagen GmbH, Hilden, Germany) and cultured in 16-24 h at 37±1°C. Interferon-gamma (IFN-γ) activity was measured using a QuantiFERON TB gold plus (Qiagen GmbH. Hilden, Germany) reagent and the DS-2 (Dynex technologies, Inc., Chantilly, Virginia, USA) enzyme-linked immunosorbent assay (ELISA) system (QuantiFERON®-TB Gold Plus, 2023), after the samples are cultured in 16-24 h at 37±1°C.

QuantiFERON®-TB gold plus: Fourth-generation test reagent, Dynex DS2: Testing equipment, positive: Latent Tuberculosis Infection (LTBI) positive, negative: LTBI negative, indeterminate: Undetermined. [Interpretation of results] positive: If Nil value is ≤8.0 and both TB1 Ag-Nil and TB2 Ag-Nil values are ≥0.35 and ≥25% of Nil value. Indeterminate: If Nil value is ≤8.0 and both TB Ag-Nil value is ≤0.35 and Mitogen-Nil value is <0.5; if Nil value is ≤8.0 and TB Ag-Nil value is ≥0.35 and <25% of Nil value and Mitogen-Nil value is <0.5; and if Nil value is >8.0. Negative: If Nil value is ≤8.0 and both TB1 Ag-Nil and TB2 Ag-Nil values are ≤0.35 and Mitogen-Nil value is ≥0.5; if Nil value is ≤8.0 and both TB1 Ag-Nil and TB2 Ag-Nil values are ≥0.35 and <25% of Nil value and Mitogen-Nil value is ≥0.5.

The results were subjected to secondary data analysis utilizing IBM SPSS Statistics (version 29.0; IBM Corp., Armonk, NY, USA) and the association between age, sex and LTBI, confirmed through IGRA, was investigated. For this purpose, multinomial logistic regression analysis was performed on the significance probability value (Fig. 1).

The Institutional Review Board (IRB) of Dankook university (IRB No. DKU 2023-04-002-002) approved this research and was shown in accordance with the principles of the Declaration of Helsinki. As data were analyzed retrospectively and patients’ personal information was not used, the requirement for informed agreement was renounced by IRB of Dankook university.

Fig. 1: Flow chart of the study

DOI: 10.3844/ajbbsp.2023.292.297
Results

According to the IGRA data reported from 2019-2022, the trend of sex-specific positivity rates by age group for men showed that the rates increased from 0-9 years 50-59 years of age and then decreased. The positivity rate was 0.03% for those aged 10-19 years, 0.54% for those aged 30-39 years, 1.32% for those aged 50-59 years and 0.45% for those aged ≥70 years. For women, the positivity rates increased from 0-9 years 50-59 years, followed by a decrease from 60-69 years. The rate was 0.01% for those aged 0-9 years, 1.13% for those aged 30-39 years, 2.33% for those aged 50-59 years and 0.40% for those aged ≥70 years. The p-value for the overall age was <0.001, indicating an important link among age and positive IGRA results. Both men and women aged 50-59 years displayed the maximum positivity rates, followed by a decline after 59 years (Table 1).

Regarding annual sex-specific IGRA positivity from 2019-2022 for men, the rate decreased from 4.28% in 2019 to 3.48% in 2022. This rate decreased from 7.35% in 2019 to 5.49% in 2022 for women. The p-value for sex was <0.001, indicating a significant difference in the positivity rates between men and women. Both sexes had a decreasing trend in the positivity rates from 2019-2022 (Table 2).

From 2019-2022, a continuous growth in the percentage of positive results, rising from 1.77% in 2019 to 3.23% in 2022. Similarly, indeterminate results also increased, going from 0.17% in 2019 to 0.48% in 2022, while the percentage of negative results saw a significant rise from 13.29% in 2019 to 32.30% in 2022. This trend of increasing percentages for positive, indeterminate and negative results is depicted in Fig. 2.

Table 1: Interferon-gamma release assay positivity rates from 2019 to 2022 according to age and sex

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Men</th>
<th>Women</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-9</td>
<td>0.00</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>10-19</td>
<td>0.03</td>
<td>0.04</td>
<td>0.05</td>
</tr>
<tr>
<td>20-29</td>
<td>0.15</td>
<td>0.50</td>
<td>0.65</td>
</tr>
<tr>
<td>30-39</td>
<td>0.54</td>
<td>1.13</td>
<td>1.23</td>
</tr>
<tr>
<td>40-49</td>
<td>0.88</td>
<td>1.92</td>
<td>2.34</td>
</tr>
<tr>
<td>50-59</td>
<td>1.32</td>
<td>2.33</td>
<td>3.10</td>
</tr>
<tr>
<td>60-69</td>
<td>0.93</td>
<td>1.09</td>
<td>1.97</td>
</tr>
<tr>
<td>≥70</td>
<td>0.45</td>
<td>0.40</td>
<td>0.01</td>
</tr>
</tbody>
</table>

The p-value for age was <0.001, indicating a significant association with the interferon-gamma release assay results

Table 2: Comparison of interferon-gamma release assay positivity rates from 2019-2022

<table>
<thead>
<tr>
<th>Year</th>
<th>Men</th>
<th>Women</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>4.28</td>
<td>7.35</td>
<td>11.63</td>
</tr>
<tr>
<td>2020</td>
<td>4.03</td>
<td>6.83</td>
<td>10.86</td>
</tr>
<tr>
<td>2021</td>
<td>4.30</td>
<td>6.67</td>
<td>10.97</td>
</tr>
<tr>
<td>2022</td>
<td>3.48</td>
<td>5.49</td>
<td>8.98</td>
</tr>
</tbody>
</table>

The significance probability value for sex was <0.001, indicating that female sex had a significant effect on the interferon-gamma release assay results

Discussion

The present study provides valuable insights regarding the trend of sex-specific IGRA positivity rates by age group. For men, the positivity rates showed an increasing trend from an average of 0-9 years 50-59 years, followed by a decrease until the age of ≥70 years. The positivity rates were 0.03% for an average of 10-19 years, 0.54% for 30-39 years, 1.32% for 50-59 years and 0.45% for ≥70 years. For women, the positivity rates showed an increasing trend from an average of 0-9 to 50-59 years, followed by a decrease from 60-69 years. The positivity rates were 0.01% for an average of 0-9 years, 1.13% for 30-39 years, 2.33% for 50-59 years and 0.40% for ≥70 years.

The average age of individuals with a positive result for LTBI obtained utilizing the QuantiFERON® TB Gold In-Tube (QFT-GIT) test in Taiwan was 58.2 years and the tendency of QFT-GIT positivity augmented after 50 years of age (Chang et al., 2022). In line with the results obtained from this study, it was noted that there were notably high positivity rates among individuals aged ≥50 years.

The probability of LTBI in individuals aged 50 years and older in this study was statistically important (p<0.001), indicating a noteworthy association. Both men and women exhibited the highest positivity rates in the age group of 50-59 years, with rates gradually decreasing after the age of 60-69 years. A study conducted in China using the QFT-GIT showed a 10.80% LTBI positivity rate (Zhao et al., 2023). In this study, the annual positivity for LTBI based on IGRA results from 2019-2022 showed a decreasing trend among men, but the rate for 2021 (4.30%) was higher than the rates for 2019 (4.28%) and 2022 (3.48%). Among women in Taiwan, the annual positivity rates were 7.35% in 2019, 6.67% in 2021 and
5.49% in 2022. These rates were found to be lower than those reported in a study conducted in China.

The p-value for sex was <0.001, indicating a significantly higher positivity rate in women for the IGRA results. Both men and women had a decreasing annual positivity rate from 2019-2022. From 2019-2022, the distributions of the positive, indeterminate and negative IGRA results showed an increasing trend. Analysis of the distribution of positive results revealed it was 1.77% in 2019, 2.67% in 2020, 2.65% in 2021 and 3.23% in 2022, with a total of 10.32%. Although it was slightly lower than 10.80% from China’s preceding study, there was not a significant difference.

According to a systematic analysis and meta-analysis of a global research conducted by authors from Germany, the prevalence of LTBI was the lowest in North American and pacific countries and the top in Eastern Mediterranean countries (Peters et al., 2020). Additionally, HCWs in Semarang, Indonesia, exhibit a high prevalence of LTBI (Erawati and Andriany, 2020). Furthermore, a study in Poland indicated that the average IFN-γ concentration in IGRA principles was meaningfully developed in the LTBI group than in children with active TB, suggesting its potential use as a selective test for children and youths unprotected to infectious TB (Druszcynska et al., 2023). An IGRA screening strategy is also effective in children in areas with low TB prevalence (Calzada-Hernández et al., 2023). Tailored interventions are required to prescription and accomplishment for patients with LTBI (Bruxvoort et al., 2023).

Analysis of the IGRA results from 2019-2022, revealed that the age of 50-59 years had the maximum positivity rate among both men and women. Furthermore, the likelihood of detecting a positive result increase with the frequency of testing. Considering the decreasing trend in yearly positivity rates, continuous testing with IGRA is necessary at healthcare institutions for individuals aged 50-59 years to monitor and manage LTBI cases effectively. Our 4-year analysis of IGRA results provides valuable insights into LTBI trends. There is a need for regular and expanded testing of high-risk groups, such as HCWs, military personnel, detainees and students.

Rifampin and isoniazid, used for LTBI treatment, can cause adverse effects such as hepatotoxicity and peripheral neuropathy (Jonas et al., 2023; Kim et al., 2023). It is important to ensure that the drugs used for treatment are safe for patients and that effective methods are developed for each step of LTBI testing and treatment (Yang et al., 2023; Cola et al., 2023). Additionally, there is a need for research on drug susceptibility for available pharmacotherapy.

This study has some limitations. First, we only analyzed the results of IGRA conducted at a single institution and the results were not compared with those obtained using other analytical methods. Second, this study did not consider the possibility of duplicate testing. Therefore, the pros and cons of IGRA can be analyzed and it is believed that it can be helpful for public health.

Conclusion

The LTBI positivity rate is high in both men and women 50-59 years of age and the IGRA positivity rate increases with the frequency of testing. Continued IGRA testing is necessary for groups such as HCWs, soldiers and students. Furthermore, it is essential to compare and analyze the results of IGRA and other testing methods as representative data in future studies conducted in Korea. This will allow for a thorough examination of the pros and cons of IGRA, with the potential to benefit public health.

Acknowledgment

We thank the employees at our testing center in Yongin, South Korea, for helping us access the Interferon-gamma release assay data.

The data used in this study were obtained from Seoul clinical laboratories (https://www.scllab.co.kr); owing to the company's policy, we are unable to make the data publicly available. The data are accessible from the corresponding author on rational request.

Funding Information

The authors have not received any financial support or funding to report.

Author’s Contributions

Tae Soung Kim and Ga Yeon Kim: Made substantial contributions to the conception and designed of the study. These authors contributed equally to this study.

Young Ki Lee and Jae Kyung Kim: Made substantial contributions and acquisition and analysis of the data.

Ethics

The authors state that there is no conflict of interest. This research was accepted by the Institutional Review Board (IRB) of Dankook University (IRB No. DKU 2023-04-002-002) and was directed in accordance with the principles of the Declaration of Helsinki. As data were analyzed retrospectively and patients’ personal information was not used, the requirement for obtaining informed agreement was renounced by the IRB of Dankook University.
References


